+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaginitis Therapeutics Market Analysis & Forecast to 2024-2034

  • PDF Icon

    Report

  • 200 Pages
  • January 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5923226
The global vaginitis therapeutics market size was estimated to be USD 3.52 billion in 2023 and is expected to reach at USD 8.74 billion by 2034 with a CAGR of 8.62% during the forecast period 2024-2034. Increasing prevalence of vaginitis, growing awareness regarding the importance of maintaining good vaginal health among women population, surge in demand for improved healthcare infrastructure, rising awareness initiatives by government & non-government organizations, increasing research & development activities by major market players, growing number of clinical trial procedures, surge in endeavors focused on the development of innovative formulations, and rising introduction of novel drugs for the treatment of vaginitis are some of the key factors boosting the market growth.

Rising introduction of novel drugs for the treatment of vaginitis is predicted to boost the market growth during the forecast period. Vaginitis is a prevalent medical condition in women, marked by previously undetected complications and morbidity. Extensive research in recent years has contributed to the development of treatment options for various forms of vaginitis. Women, especially during their reproductive years, are susceptible to vaginitis, which can be triggered by an imbalance in the vaginal microflora. Consequently, industry participants are emphasizing the creation of innovative medications for vaginitis. For instance, in July 2023, Daré Bioscience, Inc., a leader in women’s health innovation, reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon, and announced that Organon will pay Daré $1.0 million in July 2023.

By type, anti-bacterial was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the increasing prevalence of bacterial vaginosis, rising approvals by regulatory bodies for improved treatment options, and growing launch of advanced treatment options. For instance, in June 2022, Duchesnay Inc, a Canadian pharmaceutical company with a focus on women's health, has introduced Vablys, which is the first prescription antiseptic and anti-infective treatment for bacterial vaginosis in women below the age of 55. This product features multiple modes of action and anti-infective properties effective against various pathogens. Additionally, hormonal treatment is predicted to grow at fastest CAGR during the forecast period owing to the presence of strong pipeline drugs, growing prevalence of vaginitis, increasing preference for oral hormonal treatments due to their convenience & efficacy.

By route of administration, oral was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to their convenience & ease of use, increasing clinical trial procedures, and growing introduction of new products. Additionally, vaginal is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative treatment options and surge in research & development activities. For instance, in May 2023, Gedea Biotech has initiated the treatment of the first patients with its flagship product, pHyph, which is a vaginal tablet designed for topical treatment. The objective of this open-label study is to validate the safety and effectiveness of pHyph in managing adult women with confirmed Vulvo Vaginal Candidiasis (VVC) and in reestablishing a healthy vaginal microbiome to prevent the recurrence of the infection. The study is being carried out at four gynecological clinics in Sweden.

By schedule, prescription was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the enhanced effectiveness and safety of prescription medications for severe and recurrent vaginitis and surge in prescription of novel drugs by healthcare professionals. Additionally, over-the-counter (OTC) is predicted to grow at fastest CAGR during the forecast period owing to the availability of a diverse array of over-the-counter (OTC) drugs, including vaginal creams, gels, & more and increasing launch of new medications. For instance, in April 2022, Solosec (secnidazole) is an oral antibiotic intended for single-dose use. It is approved for the treatment of bacterial vaginosis in female patients aged 12 years and older, as well as for trichomoniasis in adults. Lupin Pharmaceuticals is responsible for the manufacturing and distribution of the drug, while Exeltis handles its marketing.

By distribution channel, mail order pharmacies was the highest revenue-grossing segment in the global vaginitis therapeutics market in 2023 owing to the increase in pharmaceutical sales through mail-order pharmacies and surge in demand of prescription drugs through mail & various internet outlets by patients. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of vaginitis, surge in demand for innovative treatment options, and rising collaborations within market players. For instance, in February 2023, Basilea Pharmaceutica Ltd has revealed that the robust sales performance of the antifungal medication Cresemba (isavuconazole) by its licensing partner Pfizer Inc. in the Asia Pacific region and China has surpassed the set threshold, leading to a sales milestone payment of $1.25 million.

North America region is anticipated for the highest revenue share during the forecast period owing to the surge in well-established healthcare infrastructure, growing prevalence of disease, rising favorable government initiatives, increasing awareness regarding vaginal health among women, and surge in research & development activities. For instance, in September 2023, LABthera-001, which is in clinical development by AtoGen and is currently in Phase I for the treatment of Bacterial Vaginosis, is showing promise. According to data from GlobalData, Phase I drugs for Bacterial Vaginosis have a 100% Phase Transition Success Rate (PTSR) benchmark for advancing into Phase II, suggesting a positive outlook for LABthera-001 in its development. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness about early disease diagnosis, rising focus on development of effective drugs, and growing introduction of new products. For instance, in May 2022, The Consumer Health division of Bayer has introduced an updated and enhanced line of Canesten, their anti-fungal treatment solution, in India.

Segmentation: Vaginitis Therapeutics Market Report 2023 - 2034

Vaginitis Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)

  • Anti-bacterial
  • Hormone
  • Anti-fungal

Vaginitis Therapeutics Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)

  • Cutaneous
  • Oral
  • Vaginal

Vaginitis Therapeutics Market Analysis & Forecast by Schedule 2023 - 2034 (Revenue USD Bn)

  • Prescription
  • Over-the-counter (OTC)

Vaginitis Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

  • Drug Stores
  • Hospital Pharmacies
  • Mail Order Pharmacies
  • Retail Pharmacies

Vaginitis Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global Vaginitis Therapeutics Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Vaginitis Therapeutics Market: Type Estimates & Trend Analysis
7.1. Type Segment Opportunity Analysis
7.2. Anti-bacterial
7.2.1. Anti-bacterial Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3. Hormone
7.3.1. Hormone Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4. Anti-fungal
7.4.1. Anti-fungal Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8. Vaginitis Therapeutics Market: Route of Administration Estimates & Trend Analysis
8.1. Route of Administration Segment Opportunity Analysis
8.2. Cutaneous
8.2.1. Cutaneous Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.3. Oral
8.3.1. Oral Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.4. Vaginal
8.4.1. Vaginal Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9. Vaginitis Therapeutics Market: Schedule Estimates & Trend Analysis
9.1. Schedule Segment Opportunity Analysis
9.2. Prescription
9.2.1. Prescription Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.3. Over-the-counter (OTC)
9.3.1. Over-the-counter (OTC) Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10. Vaginitis Therapeutics Market: Distribution Channel Estimates & Trend Analysis
10.1. Distribution Channel Segment Opportunity Analysis
10.2. Drug Stores
10.2.1. Drug Stores Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.3. Hospital Pharmacies
10.3.1. Hospital Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.4. Mail Order Pharmacies
10.4.1. Mail Order Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10.5. Retail Pharmacies
10.5.1. Retail Pharmacies Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
11. Regional Market Analysis
11.1. Regional Market Opportunity Analysis
12. North America Vaginitis Therapeutics Market
12.1. North America Vaginitis Therapeutics Market
12.1.1. North America Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.1.2. North America Vaginitis Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
12.1.3. North America Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
12.1.4. North America Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
12.1.5. North America Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
12.1.6. North America Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.2. U.S. Global Vaginitis Therapeutics Market
12.2.1. U.S. Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.2.2. U.S. Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
12.2.3. U.S. Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
12.2.4. U.S. Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
12.2.5. U.S. Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.3. Canada Global Vaginitis Therapeutics Market
12.3.1. Canada Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.3.2. Canada Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
12.3.3. Canada Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
12.3.4. Canada Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
12.3.5. Canada Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13. Europe Global Vaginitis Therapeutics Market
13.1. Europe Global Vaginitis Therapeutics Market
13.1.1. Europe Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.1.2. Europe Vaginitis Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
13.1.3. Europe Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.1.4. Europe Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.1.5. Europe Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.1.6. Europe Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.2. Germany Global Vaginitis Therapeutics Market
13.2.1. Germany Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.2.2. Germany Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.2.3. Germany Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.2.4. Germany Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.2.5. Germany Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.3. UK Global Vaginitis Therapeutics Market
13.3.1. UK Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.3.2. UK Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.3.3. UK Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.3.4. UK Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.3.5. UK Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.4. France Global Vaginitis Therapeutics Market
13.4.1. France Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.4.2. France Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.4.3. France Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.4.4. France Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.4.5. France Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.5. Spain Global Vaginitis Therapeutics Market
13.5.1. Spain Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.5.2. Spain Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.5.3. Spain Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.5.4. Spain Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.5.5. Spain Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.6. Italy Global Vaginitis Therapeutics Market
13.6.1. Italy Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.6.2. Italy Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.6.3. Italy Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.6.4. Italy Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.6.5. Italy Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.7. Rest of Europe Global Vaginitis Therapeutics Market
13.7.1. Rest of Europe Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.7.2. Rest of Europe Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
13.7.3. Rest of Europe Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
13.7.4. Rest of Europe Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
13.7.5. Rest of Europe Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14. Asia Pacific Global Vaginitis Therapeutics Market
14.1. Asia Pacific Global Vaginitis Therapeutics Market
14.1.1. Asia Pacific Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.1.2. Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
14.1.3. Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.1.4. Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.1.5. Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.1.6. Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.2. Japan Global Vaginitis Therapeutics Market
14.2.1. Japan Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.2.2. Japan Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.2.3. Japan Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.2.4. Japan Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.2.5. Japan Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.3. China Global Vaginitis Therapeutics Market
14.3.1. China Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.3.2. China Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.3.3. China Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.3.4. China Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.3.5. China Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.4. India Global Vaginitis Therapeutics Market
14.4.1. India Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.4.2. India Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.4.3. India Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.4.4. India Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.4.5. India Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.5. South Korea Global Vaginitis Therapeutics Market
14.5.1. South Korea Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.5.2. South Korea Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.5.3. South Korea Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.5.4. South Korea Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.5.5. South Korea Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.6. Australia Global Vaginitis Therapeutics Market
14.6.1. Australia Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.6.2. Australia Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.6.3. Australia Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.6.4. Australia Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.6.5. Australia Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.7. Rest of Asia Pacific Global Vaginitis Therapeutics Market
14.7.1. Rest of Asia Pacific Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.7.2. Rest of Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
14.7.3. Rest of Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
14.7.4. Rest of Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
14.7.5. Rest of Asia Pacific Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15. Latin America Global Vaginitis Therapeutics Market
15.1. Latin America Global Vaginitis Therapeutics Market
15.1.1. Latin America Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.1.2. Latin America Vaginitis Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
15.1.3. Latin America Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
15.1.4. Latin America Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.1.5. Latin America Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
15.1.6. Latin America Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.2. Brazil Global Vaginitis Therapeutics Market
15.2.1. Brazil Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.2.2. Brazil Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
15.2.3. Brazil Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.2.4. Brazil Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
15.2.5. Brazil Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.3. Mexico Global Vaginitis Therapeutics Market
15.3.1. Mexico Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.3.2. Mexico Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
15.3.3. Mexico Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.3.4. Mexico Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
15.3.5. Mexico Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.4. Argentina Global Vaginitis Therapeutics Market
15.4.1. Argentina Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.4.2. Argentina Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
15.4.3. Argentina Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.4.4. Argentina Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
15.4.5. Argentina Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.5. Rest of Latin America Global Vaginitis Therapeutics Market
15.5.1. Rest of Latin America Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.5.2. Rest of Latin America Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
15.5.3. Rest of Latin America Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
15.5.4. Rest of Latin America Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
15.5.5. Rest of Latin America Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
16. MEA Global Vaginitis Therapeutics Market
16.1. MEA Global Vaginitis Therapeutics Market
16.1.1. MEA Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.1.2. MEA Vaginitis Therapeutics Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
16.1.3. MEA Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
16.1.4. MEA Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.1.5. MEA Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
16.1.6. MEA Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
16.2. GCC Global Vaginitis Therapeutics Market
16.2.1. GCC Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.2.2. GCC Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
16.2.3. GCC Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.2.4. GCC Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
16.2.5. GCC Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
16.3. South Africa Global Vaginitis Therapeutics Market
16.3.1. South Africa Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.3.2. South Africa Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
16.3.3. South Africa Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.3.4. South Africa Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
16.3.5. South Africa Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
16.4. Rest of MEA Global Vaginitis Therapeutics Market
16.4.1. Rest of MEA Vaginitis Therapeutics Market Size and Forecast, 2023-2034 (Revenue USD Bn)
16.4.2. Rest of MEA Vaginitis Therapeutics Market Size and Forecast, By Type, 2023-2034 (Revenue USD Bn)
16.4.3. Rest of MEA Vaginitis Therapeutics Market Size and Forecast, By Route of Administration, 2023-2034 (Revenue USD Bn)
16.4.4. Rest of MEA Vaginitis Therapeutics Market Size and Forecast, By Schedule, 2023-2034 (Revenue USD Bn)
16.4.5. Rest of MEA Vaginitis Therapeutics Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
17. Competitor Analysis
17.1. Company Market Share Analysis, 2023
17.2. Major Recent Developments
18. Company Profiles
18.1. Daré Bioscience, Inc.
18.2. Pfizer, Inc.
18.3. Merck & Co.
18.4. Duchesnay Inc
18.5. Novartis AG
18.6. Bayer AG
18.7. Gedea Biotech
18.8. Lupin Pharmaceuticals, Inc.
18.9. Symbiomix Therapeutics, Inc.
18.10. Basilea Pharmaceutica Ltd
18.11. Mission Pharmacal Company
18.12. Other Prominent Players
19. Conclusion20. Recommendations

Companies Mentioned

  • Daré Bioscience Inc.
  • Pfizer Inc.
  • Merck & Co.
  • Duchesnay Inc
  • Novartis AG
  • Bayer AG
  • Gedea Biotech
  • Lupin Pharmaceuticals Inc.
  • Symbiomix Therapeutics Inc.
  • Basilea Pharmaceutica Ltd
  • Mission Pharmacal Company

Table Information